{
  "id": "0061c5f198871488",
  "title": "Bristol Myers' Cancer Breakthrough Breyanzi Just Won Its Fifth FDA Approval",
  "description": "On Thursday, the U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb & Co.\u2019s (NYSE:BMY) Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for adult patients with relapsed or refrac\u2026",
  "content": "On Thursday, the U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb &amp; Co.s (NYSE:BMY) Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (\u2026 [+145 chars]",
  "source": "Biztoc.com",
  "source_url": "https://biztoc.com/x/8dd38300d9a901cb",
  "published_at": "2025-12-05T13:40:59Z",
  "fetched_at": "2025-12-06T18:33:06.472112+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda",
    "drug",
    "search:drug approval FDA breakthrough"
  ],
  "location": null,
  "raw_data": {
    "source": {
      "id": null,
      "name": "Biztoc.com"
    },
    "author": "benzinga.com",
    "title": "Bristol Myers' Cancer Breakthrough Breyanzi Just Won Its Fifth FDA Approval",
    "description": "On Thursday, the U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb & Co.\u2019s (NYSE:BMY) Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for adult patients with relapsed or refrac\u2026",
    "url": "https://biztoc.com/x/8dd38300d9a901cb",
    "urlToImage": "https://biztoc.com/cdn/8dd38300d9a901cb_s.webp",
    "publishedAt": "2025-12-05T13:40:59Z",
    "content": "On Thursday, the U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb &amp; Co.s (NYSE:BMY) Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (\u2026 [+145 chars]"
  }
}